|  | HGSOC | LGSOC | MOC | EOC | CCOC | Others |
---|---|---|---|---|---|---|---|
Number of patients | 276 | 40 | 54 | 62 | 50 | 24 | |
Age at diagnosis (years) | 62.6 (10.7) | 54.4 (16) | 56.6 (17.8) | 60.8 (11.8) | 59.4 (12.2) | 62 (12.2) | |
Overall survival (months) | 34 (17 to 60) | 80 (50 to 107.2) | 63 (16 to 108) | 90 (59 to 120) | 52.5 (30.5 to 108.8) | 44 (2 to 88.5) | |
Vital status | Data available | 272 (99%) | 38 (95%) | 53 (98%) | 61 (98%) | 48 (96%) | 23 (96%) |
 | Alive | 69 (25%) | 30 (79%) | 26 (49%) | 36 (59%) | 19 (40%) | 11 (48%) |
 | Died | 203 (75%) | 8 (21%) | 27 (51%) | 25 (41%) | 29 (60%) | 12 (52%) |
Stage | Data available | 270 (98%) | 40 (100%) | 52 (96%) | 62 (100%) | 48 (96%) | 24 (100%) |
 | I | 41 (15%) | 24 (60%) | 42 (81%) | 36 (58%) | 28 (58%) | 8 (33%) |
 | II | 31 (11%) | 3 (8%) | 1 (2%) | 13 (21%) | 8 (17%) | 1 (4%) |
 | III | 168 (62%) | 12 (30%) | 7 (13%) | 11 (18%) | 12 (25%) | 12 (50%) |
 | IV | 30 (11%) | 1 (2%) | 2 (4%) | 2 (3%) | 0 (0%) | 3 (12%) |
Grade | Data available | 197 (71%) | 21 (52%) | 39 (72%) | 60 (97%) | 38 (76%) | 10 (42%) |
 | I | 1 (1%) | 20 (95%) | 18 (46%) | 10 (17%) | 0 (0%) | 2 (20%) |
 | II | 4 (2%) | 0 (0%) | 15 (38%) | 17 (28%) | 0 (0%) | 1 (10%) |
 | III | 192 (97%) | 1 (5%) | 6 (15%) | 33 (55%) | 38 (100%) | 7 (70%) |
PTEN status (IHC) | Data available | 233 (84%) | 34 (85%) | 40 (74%) | 55 (89%) | 43 (86%) | 23 (96%) |
 | Negative | 27 (12%) | 1 (3%) | 4 (10%) | 18 (33%) | 14 (33%) | 5 (22%) |
 | Weak positive | 65 (28%) | 5 (15%) | 17 (42%) | 13 (24%) | 17 (40%) | 6 (26%) |
 | Heterogeneous | 29 (12%) | 0 (0%) | 3 (8%) | 0 (0%) | 1 (2%) | 5 (22%) |
 | Positive | 112 (48%) | 28 (82%) | 16 (40%) | 24 (44%) | 11 (26%) | 7 (30%) |